Screen one COA, compare a shortlist, or hand the whole job to us. And if you're not sure who to buy from, we'll point you to the evidence — free.
What's in your report:
Systematic coverage of 15 key peptides — BPC-157, TB-500, GHK-Cu, Retatrutide, Semaglutide, Tirzepatide, CJC-1295, Ipamorelin, KPV, MOTS-c, NAD+, AOD9604, Cagrilintide, Selank, Epitalon — plus any peptide with a COA you upload.
Your first review is free. Delivered in the app in under 2 minutes. Comparison report — up to 3 providers on Proof, Price & Match — A$44.
Some suppliers sponsor free reviews of their own COAs. Got a PEPI- code? Redeem it in the app — same independent scoring, no exceptions.
Deep-dive reports you can buy and keep — researched, sourced, and written in plain language.
A 12-page, fully-referenced guide (19 sources): the 2014 compounding-clinic era, the ~2019 US crackdown and 2026 reversal, the Croatia BPC-157 story, China’s TESTS trial — and an honest evidence-vs-placebo scorecard on the healing, anti-aging and libido claims.
Send me the guide →Delivered as a PDF after quick email verification — available in English & 中文 (简体).
Full access to PepiScreen for prescribers, informed buyers, and industry professionals working with a peptide-literate clinician.
Membership pricing under review — enquire below to be notified when public pricing is confirmed. Membership does not include supply of peptides. See our regulatory position and Statement of Assurance.
Enquire about Membership →Independent 12-page guide to the peptide market — for buyers, prescribers and suppliers alike. Free after quick email verification.
Independent market intelligence for buyers, prescribers and suppliers. No spam, no sponsors, no affiliates. Your details are only used to send the guide and occasional PepiScreen updates — unsubscribe anytime.
Tell us the peptide you're after and we'll refer you to the highest-scoring, evidence-screened suppliers from our directory — chosen on documentation, never on who paid. It's free, and there's no obligation.
Referrals follow the evidence — suppliers can't pay to be recommended. Want the full picture? A 3-supplier comparison shows how your shortlist stands against each other, not just against the market.